Multiple Sclerosis: all 3,524 studies

Page 10 of 36. Open to participants first (668), then studies with results posted, then the rest; newest registration first within each.

• Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple SclerosisTerminatedNCT02296346Not applicableResults posted
• Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)CompletedNCT02294058Phase 3Results posted
• Effects of Acthar on Recovery From Cognitive Relapses in MSCompletedNCT02290444Phase 3Results posted
• A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to PlaceboCompletedNCT02284568Phase 2Results posted
• Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple SclerosisCompletedNCT02280096Phase 2Results posted
• Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)CompletedNCT02258217Not applicableResults posted
• Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409CompletedNCT02255656Phase 4Results posted
• Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™CompletedNCT02254304Phase 4Results posted
• Exploring the Use of Non-invasive Neuromodulation Combined With Exercise in People With Advanced Multiple Sclerosis (MS)CompletedNCT02252666Not applicableResults posted
• Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other TherapiesTerminatedNCT02241785Phase 4Results posted
• Adherence in Pediatric Multiple SclerosisCompletedNCT02234713Not applicableResults posted
• Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular RisksCompletedNCT02232061Phase 4Results posted
• Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple SclerosisCompletedNCT02219932Phase 3Results posted
• Pilot Study to Assess Dimethyl Fumarate Related GI Symptom MitigationTerminatedNCT02217982Phase 4Results posted
• A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MSCompletedNCT02208050Phase 4Results posted
• Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple SclerosisCompletedNCT02201108Phase 3Results posted
• Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis PatientsCompletedNCT02184494Not applicableResults posted
• Developing and Testing a Comprehensive MS Spasticity Management ProgramCompletedNCT02170779Phase 2Results posted
• Neuromuscular Electrical Stimulation and Mobility in Multiple SclerosisCompletedNCT02152085Not applicableResults posted
• Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple SclerosisCompletedNCT02133664Phase 1/2Results posted
• Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In GermanyCompletedNCT02125604Phase 4Results posted
• RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl FumarateTerminatedNCT02117050Phase 4Results posted
• Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.CompletedNCT02097849Phase 2Results posted
• Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT02090413Phase 4Results posted
• Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple SclerosisCompletedNCT02086188Phase 4Results posted
• A Study of Rebif® in Subjects With Relapsing Multiple SclerosisCompletedNCT02064816Phase 4Results posted
• Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MSCompletedNCT02048072Phase 4Results posted
• Efficacy and Safety Study of Ozanimod in Relapsing Multiple SclerosisCompletedNCT02047734Phase 3Results posted
• A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)TerminatedNCT02045732Phase 1Results posted
• Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune DiseasesCompletedNCT02040116Phase 4Results posted
• A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple SclerosisTerminatedNCT02038049Phase 2Results posted
• Electric Stimulation of the Eye to Improve Vision After TraumaCompletedNCT02019927Not applicableResults posted
• Rebif® Rebidose® Versus Rebiject II® Ease-of-UseCompletedNCT02019550Phase 4Results posted
• Effects of Dalfampridine on Cognition in Multiple SclerosisCompletedNCT02006160Phase 2/3Results posted
• Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple SclerosisCompletedNCT01982942Phase 2Results posted
• ATX-MS-1467 in Multiple SclerosisCompletedNCT01973491Phase 2Results posted
• MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCVCompletedNCT01970410Phase 4Results posted
• A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis PatientsCompletedNCT01964547Phase 4Results posted
• Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)TerminatedNCT01963611Phase 2Results posted
• ACTH in Progressive Forms of MSTerminatedNCT01950234Phase 2Results posted
• The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS)CompletedNCT01947582Not applicableResults posted
• Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)CompletedNCT01939002Phase 3Results posted
• Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice PatternsCompletedNCT01930799Phase 4Results posted
• A Randomized Trial of Two Formal Group Programs for Multiple SclerosisCompletedNCT01918800Not applicableResults posted
• Measurement of Relaxin Peptide in Multiple Sclerosis (MS)CompletedNCT01909492Results posted
• Methylphenidate to Improve Balance and Walking in MSCompletedNCT01896700Phase 2/3Results posted
• Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsCompletedNCT01895335Phase 4Results posted
• Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple SclerosisActive, not recruitingNCT01892722Phase 3Results posted
• Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple SclerosisTerminatedNCT01874340Phase 2Results posted
• Safety and Tolerability of Glatiramer AcetateCompletedNCT01874145Phase 3Results posted
• Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United StatesCompletedNCT01873417Phase 4Results posted
• Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With AvonexCompletedNCT01864148Phase 2Results posted
• Idebenone for Primary Progressive Multiple SclerosisCompletedNCT01854359Phase 1/2Results posted
• Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis MedicationsCompletedNCT01834586Phase 4Results posted
• Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019TerminatedNCT01797965Phase 3Results posted
• Effectiveness of Ankle Foot Orthoses on Gait in Multiple SclerosisTerminatedNCT01796860Not applicableResults posted
• A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ DeviceCompletedNCT01791244Phase 4Results posted
• Raltegravir (Isentress) Pilot Study in Relapsing Multiple SclerosisCompletedNCT01767701Phase 2Results posted
• Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS PatientsCompletedNCT01767493Phase 4Results posted
• The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT01707992Phase 3Results posted
• A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®CompletedNCT01705236Phase 4Results posted
• Pharmacokinetics of Vitamin D in Multiple Sclerosis and in HealthCompletedNCT01667796Not applicableResults posted
• Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)CompletedNCT01665144Phase 3Results posted
• Assessing Tolerability of Avonex Intramuscular InjectionsCompletedNCT01641120Not applicableResults posted
• MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus CopaxoneTerminatedNCT01633112Phase 3Results posted
• Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis PatientsCompletedNCT01628393Phase 2/3Results posted
• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.CompletedNCT01623596Phase 4Results posted
• Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple SclerosisCompletedNCT01615887Phase 2Results posted
• An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple SclerosisCompletedNCT01610713Phase 3Results posted
• An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis PatientsCompletedNCT01610700Phase 3Results posted
• A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple SclerosisCompletedNCT01610687Phase 3Results posted
• Stem Cells in Rapidly Evolving Active Multiple SclerosisCompletedNCT01606215Phase 1/2Results posted
• A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological OriginCompletedNCT01606176Phase 3Results posted
• A Study of the Long-term Safety of Sativex UseCompletedNCT01606137Phase 3Results posted
• A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple SclerosisCompletedNCT01604265Phase 3Results posted
• Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)CompletedNCT01600716Phase 3Results posted
• A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple SclerosisCompletedNCT01599234Phase 3Results posted
• Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple SclerosisCompletedNCT01585766Phase 1Results posted
• STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)CompletedNCT01585298Phase 4Results posted
• An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)TerminatedNCT01578785Phase 3Results posted
• A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720CompletedNCT01578330Phase 4Results posted
• Promoting Physical Activity Behavior in Persons With Multiple SclerosisCompletedNCT01572207Not applicableResults posted
• Comparison of Rituximab Induction Therapy Followed by Glatiramer AcetateCompletedNCT01569451Phase 2Results posted
• An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)CompletedNCT01535664Results posted
• Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)CompletedNCT01534182Phase 4Results posted
• Phase Ib Study to Evaluate MOR103 in Multiple SclerosisCompletedNCT01517282Phase 1/2Results posted
• Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1aCompletedNCT01514370Phase 2Results posted
• Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to FingolimodTerminatedNCT01499667Phase 3Results posted
• Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying TherapyCompletedNCT01498887Phase 4Results posted
• Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01497262Phase 3Results posted
• Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple SclerosisTerminatedNCT01490840Phase 4Results posted
• Vitamin D Supplementation in Multiple SclerosisCompletedNCT01490502Phase 3Results posted
• Efficacy and Safety of GTR in Comparison to Copaxone®CompletedNCT01489254Phase 3Results posted
• Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple SclerosisCompletedNCT01480076Phase 4Results posted
• An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple SclerosisCompletedNCT01462318Phase 3Results posted
• Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple SclerosisCompletedNCT01457924Phase 2Results posted
• The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple SclerosisCompletedNCT01455220Not applicableResults posted
• Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer AcetateCompletedNCT01454791Phase 4Results posted
• Safety and Neuroprotective Effects of Polyphenon E in MS; Phase IITerminatedNCT01451723Phase 2Results posted
• Prospective Randomized Endovascular Therapy in Multiple Sclerosis - PREMiSECompletedNCT01450072Not applicableResults posted

← Multiple Sclerosis overview